Metronomic chemotherapy for metastatic prostate cancer: A "young"concept for old patients?

Drugs and Aging

Volumn 27, Issue 9, 2010, Pages 689-696

  Fontana, Andrea ^a   Falcone, Alfredo ^a,b   Derosa, Lisa ^a   Di Desidero, Teresa ^b   Danesi, Romano ^b   Bocci, Guido ^b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Celecoxib, therapeutic use; Cyclophosphamide, therapeutic use; Dexamethasone, therapeutic use; Docetaxel, therapeutic use; Elderly; Prostate cancer, treatment

Indexed keywords

CELECOXIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; METHOTREXATE; PREDNISONE;

ANEMIA; ANOREXIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHOLESTASIS; CLINICAL TRIAL; DIARRHEA; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GERIATRICS; GRANULOCYTOPENIA; HUMAN; INSOMNIA; KIDNEY DISEASE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MELANOMA; NAIL COLOR DEFECT; NAUSEA; NEUTROPENIA; NOTE; PALLIATIVE THERAPY; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RASH; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 77956377905     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11537480-000000000-00000     Document Type: Note

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009 Jul-Aug; 59 (4): 225-249
2. Mohile SG, Lachs M, Dale W. Management of prostate cancer in the older man. Semin Oncol 2008 Dec; 35 (6): 597-617
3. Shepard DR, Raghavan D. Innovations in the systemic therapy of prostate cancer. Nat Rev Clin Oncol 2010 Jan; 7 (1): 13-21
4. Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009 Feb; 6 (2): 76-85
5. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 Oct 7; 351 (15): 1513-1520
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 Oct 7; 351 (15): 1502-1512
7. Lin AM, Small EJ. Management of hormone refractory prostate cancer. Curr Opin Support Palliat Care 2007 Oct; 1 (3): 187-191
8. Beer TM, Berry W, Wersinger EM, et al. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2003 Dec; 2 (3): 167-172
9. Falci C, Morello E, Droz JP. Treatment of prostate cancer in unfit senior adult patients. Cancer Treat Rev 2009 Oct; 35 (6): 522-527
10. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008 Jan 10; 26 (2): 242-245
11. Italiano A, Ortholan C, Oudard S, et al. Docetaxel-basedchemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009 Jun; 55 (6): 1368-1375
12. Glode LM, Barqawi A, Crighton F, et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003 Oct 15; 98 (8): 1643-1648
13. Lord R, Nair S, Schache A, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007 Jun; 177 (6): 2136-2140
14. Fontana A, Galli L, Fioravanti A, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 2009 Aug 1; 15 (15): 4954-4962
15. Nelius T, Klatte T, de RieseW, et al. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol 2010 Jun; 27 (2): 363-367
16. Fontana A, Bocci G, Galli L, et al. Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. J Am Geriatr Soc 2010 May; 58 (5): 986-988
17. Dellapasqua S, Bertolini F, Bagnardi V, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008 Oct 20; 26 (30): 4899-4905
18. Allegrini G, Falcone A, Fioravanti A, et al. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer 2008 Apr 22; 98 (8): 1312-1319
19. Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006 Sep; 17 (8): 961-967
20. Bocci G, Tuccori M, Emmenegger U, et al. Cyclophosphamide- methotrexate metronomic chemotherapy for the palliative treatment of metastatic breast cancer: a comparative pharmacoeconomic evaluation. Ann Oncol 2005 Aug; 16 (8): 1243-1252
21. Yamashita K, Nabeshima A, Kondo H, et al. A case of metronomic chemotherapy as an alternative cancer therapy for palliation. Nippon Ronen Igakkai Zasshi 2009 May; 46 (3): 264-268
22. NanniniM, Nobili E, Di Cicilia R, et al. To widen the setting of cancer patients who could benefit from metronomic capecitabine. Cancer Chemother Pharmacol 2009 Jun; 64 (1): 189-193
23. Borne E, Desmedt E, Duhamel A, et al. Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs. Epub 2009 Aug 12
24. Sung CC, Chang PY, Cheng MF, et al. Successful metronomic low-dose cyclophosphamide therapy in an older patient with advanced mucosa-associated lymphoid tissue lymphoma. Ann Hematol 2009 Dec; 88 (12): 1257-1259
25. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008 Jan 1; 26 (1): 76-82
26. Arnoldi E, Dieli M, Mangia M, et al. Metronomic chemotherapy in elderly patients: do risks exceed benefits in some patients? Tumori 2007 Nov-Dec; 93 (6): 647
27. Crivellari D, Colleoni M, Dellapasqua S, et al. Metronomic chemotherapy in elderly patients: do risks exceed benefits in some patients? [letter]. Tumori 2009 Jan-Feb; 95 (1): 130; author reply 1
28. Bocci G, Francia G, Man S, et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 2003 Oct 28; 100 (22): 12917-12922
29. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002 May 15; 62 (10): 2731-2735
30. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.Cancer Immunol Immunother 2007 May; 56 (5): 641-648